國立虎尾科技大學 |

Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders/ by Shabir Ahmad Ganai.
作者:	Ganai, Shabir Ahmad.
面頁冊數:	XVII, 93 p. 8 illus., 5 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Neurosciences. -
電子資源:	https://doi.org/10.1007/978-981-13-8019-8
ISBN:	9789811380198

Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders
Ganai, Shabir Ahmad.

Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders[electronic resource] /by Shabir Ahmad Ganai. - 1st ed. 2019. - XVII, 93 p. 8 illus., 5 illus. in color.online resource.

Chapter 1. Role of Epigenetics in neurological diseases -- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens -- Chapter 3. Distinct classes of HDACs -- Chapter 4. HDAC implications in neurological diseases -- Chapter 5. HDAC inhibitors and their structurally distinct groups -- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders -- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies -- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy -- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents -- Chapter 10. Future directions of epigenetic research in tackling neurological complications.

This book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs). It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors’ therapeutic efficacy against various neurological complications.

ISBN: 9789811380198

Standard No.: 10.1007/978-981-13-8019-8doiSubjects--Topical Terms:

593561
Neurosciences.

LC Class. No.: RC321-580

Dewey Class. No.: 612.8

Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders
LDR:03212nam a22003975i 4500 001 1003685
003 DE-He213
005 20200705045645.0
007 cr nn 008mamaa
008 210106s2019 si | s |||| 0|eng d
020 $a 9789811380198 $9 978-981-13-8019-8
024 7 $a 10.1007/978-981-13-8019-8 $2 doi
035 $a 978-981-13-8019-8
050 4 $a RC321-580
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 612.8 $2 23
100 1 $a Ganai, Shabir Ahmad. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1297066
245 1 0 $a Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders $h [electronic resource] / $c by Shabir Ahmad Ganai.
250 $a 1st ed. 2019.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2019.
300 $a XVII, 93 p. 8 illus., 5 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Chapter 1. Role of Epigenetics in neurological diseases -- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens -- Chapter 3. Distinct classes of HDACs -- Chapter 4. HDAC implications in neurological diseases -- Chapter 5. HDAC inhibitors and their structurally distinct groups -- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders -- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies -- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy -- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents -- Chapter 10. Future directions of epigenetic research in tackling neurological complications.
520 $a This book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs). It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors’ therapeutic efficacy against various neurological complications.
650 0 $a Neurosciences. $3 593561
650 0 $a Pharmacology. $3 583819
650 0 $a Genetics. $3 578972
650 0 $a Proteins . $3 1253493
650 0 $a Posttranslational modification. $3 1253492
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Genetics and Genomics. $3 1229010
650 2 4 $a Protein Science. $3 782127
650 2 4 $a Posttranslational Modification. $3 786934
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811380181
776 0 8 $i Printed edition: $z 9789811380204
776 0 8 $i Printed edition: $z 9789811380211
856 4 0 $u https://doi.org/10.1007/978-981-13-8019-8
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)